ArticleOncogene2026
iPalmT: a new paradigm for palmitoyltransferase discovery via end-to-end deep learning.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Protein S-palmitoylation, a dynamic lipid modification, is essential for protein stability, trafficking, and signaling; dysregulated palmitoyltransferases drive cancer, yet systematic discovery of palmitoyltransferases remains hindered by labor-intensive, motif-dependent assays. We present iPalmT, an end-to-end deep learning framework that identifies palmitoyltransferases directly from primary amino acid sequence without handcrafted features or prior domain annotations. The model combines convolutional layers and squeeze-and-excitation mechanisms to capture local sequence signals and long-range dependencies. On an independent test set, iPalmT achieved 0.99 accuracy, 0.98 precision, 0.97 recall, and 0.98 F1 score. Integrated Gradients attribution emphasized the canonical DHHC motif and highlighted additional putative functional domains, despite receiving no motif supervision. Proteome-scale application to human sequences yielded unreviewed candidates; two (A0A0D9SEX5 and A0A1W2PRJ8) underwent structural analysis and experimental validation, which supported the predictions. We further release a large predicted palmitoyltransferase resource comprising 10,365,644 sequences identified from 147,847,003 proteins across 33,285 species-level groups to support large-scale exploration and cross-species analyses. iPalmT is available as a standalone program ( https://github.com/Tengda-Li-Lab/iPalmT.git ), offering a scalable, sequence-only route to discover noncanonical, evolutionarily divergent palmitoyltransferases.
Indexed as
Identifiers
42000924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.